TRACON develops targeted therapies for cancer and age-related macular degeneration. TRACON's current pipeline includes two clinical stage product candidates: TRC105, an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types, and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. Both TRC105 and TRC102 are being developed for treatment in combination with currently available therapies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/24/14 | $27,000,000 | Series B |
Arcus Ventures BHP BioMed Ventures Brookline Investments Icon Ventures Nextech Invest | undisclosed |
